The gel-forming MUC5AC and MUC5B mucins have been identified as major components of human airway mucus but it is not known whether additional mucin species, possibly with other functions, are also present. MUC16 mucin is a well known serum marker for ovarian cancer, but the molecule has also been found on the ocular surface and in cervical secretions suggesting that it may play a role on the normal mucosal surface. In this investigation, the 
INTRODUCTION
The CA 125 antigen, which was first detected by Bast et al. in 1981 using the OC125 monoclonal antibody, provides the basis for assays to detect and monitor the progression of epithelial ovarian cancer. The antigen is now known to be carried by a large mucin-like molecule encoded by the MUC16 gene Yin, Dnistrian & Lloyd, 2002) .
The MUC16 apoprotein is predicted to be very large, with three major domains: a glycosylated N-terminal domain of approximately 1600 amino acids, a large glycosylated repeat domain containing around 60 repeats of a 156 amino acid sequence and a C-terminal domain (O'Brien et al., 2001; . Since the publication of the original sequence data, O'Brien et al. have described an extension to the N-terminal domain which would extend the molecule by a further 10,431 amino acids (O'Brien, Beard, Underwood, & Shigemasa, 2002) . The predicted C-terminal of ovarian MUC16 includes a transmembrane sequence suggesting that, in this tissue, the molecule is tethered in the cell membrane. The presence of a SEA module is a characteristic feature of cell-associated mucins, but MUC16 differs from the others in that six such modules are present; the most C-terminal being located between the repeat and the transmembrane domains (O'Brien et al., 2001) . While the GSVVV motif, identified as a site of cleavage in MUC1, MUC3 and MUC12 (Khatri, Wang, & Forstner, 2003; Palmai-Pallag et al., 2005; Parry et al., 2001 ) is not present in MUC16, the most C-terminal SEA domain contains a related sequence although it has not been shown that the apoprotein undergoes cleavage in this region.
Due to its use as an ovarian tumour marker, much of the work carried out to date on CA125/MUC16 has focused on its potential involvement in the development and progression of cancer. However, MUC16 has also been detected in cervical mucus (Nustad et al., 2002) and corneal epithelial cells (Argueso, Spurr-Michaud, Russo, Tisdale, & Gipson, 2003) , suggesting that it may be a component of normal mucosal secretions at some sites. In the -Human airway MUC16 -5/14/2007 4 airway, large oligomeric mucins: MUC5AC derived mainly from the goblet cells (Hovenberg, Davies, & Carlstedt, 1996) and MUC5B originating largely from the submucosal gland mucous cells (Wickström, Davies, Eriksen, Veermann, & Carlstedt, 1998) have been identified as the major components of the mucus gel network. However in our studies, where airway tissue was metabolically labelled with 35 S-sulphate or 3 H-monosaccharides, radiolabelled "mucin-like" molecules were also present in secretions (Somerville et al., 1992; Svitacheva, Hovenberg, & Davies 1998; Svitacheva, & Davies, 2001) . The size and monomeric nature of these molecules is compatible with that of cell-associated mucins, for instance, MUC16 and MUC4. (Svitacheva, Hovenberg, & Davies, 1998) . Although found in baseline secretions, release of mucin-like molecules from human and feline airways was increased in response to bacterial exoproducts such as mono-rhamnolipid from the airway pathogen Pseudomonas aeruginosa (Somerville et al., 1992) suggesting that these molecules play an important role in airway mucosal responses to bacteria.
The aim of this investigation was to determine whether, and if so where, MUC16 is produced in human airways. Since previous studies have suggested that mucin-like molecules may be important in mucosal responses to bacteria (Somerville et al., 1992) , we also set out to determine whether such components could correspond to MUC16. Aberrant glycosylation is a common feature of carcinoma-associated mucins and antibodies raised against tumourderived molecules may thus recognize epitopes which are masked, or are not present in their "normal" counterparts. To avoid such potential problems, a novel MUC16 peptide antibody (LUM16-2) recognizing a sequence in the N-terminal domain, predicted to be largely unglycosylated, was developed and used in this study. As a tool to study whether cleavage analogous to that in other cell-associated mucins e.g. MUC1 occurs in MUC16, a second peptide antibody (LUM16-4), recognizing the C-terminal domain of the molecule, was also developed.
MATERIALS AND METHODS

Materials and analytical methods
CHAPS and guanidinium chloride (GdmCl) were from Fluka and Na 2 35 SO 4 and Sepharose CL-2B gel from Amersham Biosciences. Fractions from density-gradients were analyzed for density by weighing aliquots and absorbance at 280 nm. Carbohydrate was detected as described previously (Nordman et al., 2002) . Aliquots from radiolabelled fractions were mixed with Ready Safe (Beckman Instruments) and counted in a Wallac Guardian 1414 ß-scintillation counter.
Antibodies
The 214D4monoclonal antibody, recognizing MUC1, was kindly provided by Dr J. Hilkens, Netherlands Cancer Inst. Amsterdam, The Netherlands. The LUM2-3, LUM5B-2 and LUM5-1 antisera, recognizing MUC2, MUC5B and MUC5AC respectively, have been described previously (Hovenberg, Davies, & Carlstedt, 1996; Wickström, Davies, Eriksen, Veermann, & Carlstedt, 1998) . The sequences NLQYEEDMRHPG (in the repeat domain of MUC16 upstream of the binding sites for the OC 125 and M11 classes of antibodies) and RRRKKEGEYNVQQQC (in the MUC16 cytoplasmic tail) were used to raise LUM16-2 and LUM16-4 polyclonal antisera ( Figure 1a ). Peptides conjugated to keyhole-limpet haemocyanin (approx. 100 μg) were injected into rabbits in Freund's complete adjuvant. A booster dose of antigen in Freund's incomplete adjuvant was given after 4 weeks and the antisera collected 2 weeks later. The LUM16-2 and LUM16-4 antisera were affinity-purified against the peptide used for immunization. Working dilutions of the affinity-purified antisera are expressed relative to the original serum.
Immunohistochemistry
Sections (4 μm) of formalin fixed human tracheal tissue from a trauma victim without evidence of respiratory tract or other diseases were dewaxed, rehydrated and stained with 1%
Alcian blue in 3% acetic acid, pH 2.5 for 5 minutes at room temperature and washed with water prior to oxidation with 1% periodic acid in 3% acetic acid for 5 minutes followed by staining with Schiffs reagent for a further 5 minutes. Sections for immunohistochemistry were treated with 10 mM sodium citrate buffer, pH 6, at 100 °C for 5 min followed by 3% (v/v) hydrogen peroxide in water for 30 min. Non-specific binding was blocked with normal goat serum (1:5 in TBS) for 1 h and endogenous biotin blocked with the DAKO biotin blocking kit above. For pulse-chase experiments, cells were radiolabelled for 1 hour after which the medium was replaced with "cold" ALI medium. Apical secretions were collected after the pulse (time 0) and 1, 2 and 4 hours of chase.
Air-liquid interface cultures
Purification of mucins from the culture medium and NHBE cell layers
Apical secretions were centrifuged (36 000rpm, 45 min, Beckman 70.1Ti rotor) to separate the gel and sol phases. An equal volume of 6M GdmCl, 10 mM sodium phosphate buffer, pH 6.5 containing 5 mM sodium EDTA, 5 mM N-ethyl maleimide, 0.1 mM difluorophosphate (extraction buffer) was added to the sol prior to exhaustive dialysis against the same buffer at 4 o C. The gel phase was extracted three times overnight at 4 o C in extraction buffer. Cell layers were treated with extraction buffer containing 0.1% CHAPS. Samples (sol, gel and cell extract) were mixed with CsCl and 10 mM sodium phosphate buffer, pH 6.5 containing 5 mM sodium EDTA to an initial density of 1.39 g/ml and subjected to isopycnic density-gradient centrifugation (36 000 rpm, 15°C, 80 h, 50.2 Ti rotor, Beckman Optima L-70 centrifuge).
ELISA and radioimmunoprecipitation
Samples (100μl) from density-and rate-zonal gradients and gel chromatography runs as well as appropriate positive and negative controls for the antibodies were coated onto multiwell assay plates for 18 h at room temperature. The plates were blocked for 1 h with 0.15M NaCl, All samples studied with the LUM2-3 and LUM5B-2 antisera were subjected to reduction and alkylation before analysis as described previously cells (Hovenberg, Davies, & Carlstedt, 1996; Wickström, Davies, Eriksen, Veermann, & Carlstedt, 1998) . Reactivity was detected using an alkaline phosphatase-conjugated swine anti-rabbit serum diluted 1:2000 in blocking solution with nitrophenyl phosphate (2mg/ml in 5mM
MgCl 2 , 1M diethanolamine buffer, pH 9.8) as a substrate. Reactivity was expressed as absorbance at 405 nm after 1 h. Immunoprecipitation with the OC125 antibody was performed as described by Yin et al., 1996 and the solubilized precipitates counted in a Wallac Guardian 1414 ß-scintillation counter or subjected to agarose gel electrophoresis.
Normal mouse serum was used as a control.
Gel Chromatography and Rate-zonal Centrifugation
Fractions pooled as shown in Figure 3c were run before and after reduction/alkylation on a Sepharose CL-2B column eluted with 4M GdmCl, pH 7. Fractions (1ml) were analyzed for radioactivity and reactivity with the LUM16-2, LUM5B-2 and 214D4 antibodies. For ratezonal centrifugation, samples (100 μl) in 5 M guanidinium chloride were layered onto a gradient of 6-8 M guanidinium chloride, 10 mM sodium phosphate buffer, pH 7 and spun in a Beckman SW-41 rotor at 40 000 rpm, 20°C for 4 h. Fractions (300 μl) were taken from the top of the tubes and analysed for [ 35 S]sulphate and LUM16-2 or LUM5B-2 reactivity.
Gel Electrophoresis and Western Blotting
Concentrated material from the Sepharose CL-2B column ( Figure 4a , pool B) was subjected to electrophoresis on a 1% (w/v) agarose gel at 30 V for 16 h as described previously (Thornton et al., 1996) . The gel was equilibrated in 60mM sodium citrate buffer, pH 7 containing 0.6M NaCl, and the molecules transferred to nitrocellulose (pore size 0.45μm) by vacuum blotting in the same buffer at 4.0 kPa for 6h with a VacuGene XL blotter (Amersham Biosciences). Membranes were then either dried and exposed to Agfa Cronex 5 film or blocked for 1 h with blocking solution followed by 1 h incubation with the 214D4 antiserum diluted 1:50 in blocking solution. Reactivity was detected using a horseradish peroxidaseconjugated goat anti-rabbit serum diluted 1:2000 in blocking solution.
Secretions from three individuals with no clinical signs of respiratory disease were collected by expectoration after rinsing of the oral cavity to reduce salivary contamination and mixed with an equal volume of 6M GdmCl, 10 mM sodium phosphate buffer, pH 6. Cell layers from two independent cultures of NHBE cells were extracted at 4 o C in RIPA buffer (150mM NaCl, 50mM Tris, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 1mM
PMSF, 1mM NaV and 0.3 trypsin inhibitory units aprotinin). The lysates were cleared by centrifugation, dialysed against water and lyophilized. Cell extracts, or reduced/alkylated gel from secretions of two independent cell cultures (dialysed against water and lyophilized)
were suspended in SDS loading buffer and 20μg/well loaded onto Novex 4-12% Bis-Tris polyacrylamide gels as run as above. After electroblotting, membranes were blocked with 5% skim milk and detected using LUM16-2 or LUM16-4 antisera (diluted 1:100 in 5% skim milk) and binding visualized as above.
Mass Spectroscopy
Fractions ( Figure 4c , pool A) were dialyzed against water, lyophilized and digested overnight at 37°C with 1μg of trypsin per 10μg of protein in 100 mM ammonium bicarbonate, pH 8.0.
Tryptic peptides were separated from high M r -glycopeptides using a Sephacryl S-100 column eluted with 100 mM ammonium bicarbonate, pH 8.0 and lyophilized. Peptides were solubilized in 0.1% formic acid and separated by reverse-phase chromatography and analyzed in-line by positive ion ESI-MS-MS using a Q-ToF micro mass spectrometer (Waters, Manchester, UK). Samples were introduced via a capillary liquid chromatography system fitted with a stream select module (Waters, Manchester, UK). Aliquots (10-50μl) of the samples were separated on a Pepmap column (0.075 x 150mm) with a gradient of 5% acetonitrile in 0.1% formic acid to 25% acetonitrile in 0.1% formic acid over 30 min at a rate of 200 nl/min. Data acquired was analyzed using SwissProt and Trembl databases with the Proteinlynx global server 1.1 software (Waters, Manchester, UK). Parameters were set to 100 milliDa peptide mass tolerance, methionine oxidation and carboxyamidomethyl cysteine modification.
RESULTS
MUC16 is produced in human tracheal secretory cells
The LUM16-2 antiserum, raised against a sequence in the repeat domain of MUC16 ( Figure   1a ), was used to stain human tracheal tissue. MUC16 mucins were identified in some epithelial cells and as a layer on the luminal surface at the base of the cilia (Figure 1b) . 
MUC16 is present in normal human respiratory tract mucus and secretions from cultured bronchial epithelial cells
To investigate the presence of MUC16, normal human airway secretions were subjected to SDS-PAGE followed by Western blotting with the LUM16-2 or M11 antiserum (Figure 2) . In the three individuals tested, both antisera stained a band which only just entered the top of the gel and is likely to correspond to the large N-terminal domain of MUC16 showing that MUC16 is a component of normal human airway secretions. The presence of MUC16 in secretions from NHBE cells was studied using density-gradient centrifugation. In both the sol and the gel phases, a carbohydrate assay identified glycosylated molecules between 1.50 and 1.43g/ml co-distributing with a peak of [ 35 S]sulphate label (Figure 3a&c ). LUM16-2 reactivity revealed MUC16 mucins at 1.46g/ml coinciding with the radiolabel. A population of MUC5B mucins was found at a lower density (1.41g/ml) together with MUC1 mucins as visualized with the 214D4 antibody (Figure 3b&d ). The LUM5-1 and LUM2-3 antisera showed no reactivity suggesting that MUC5AC and MUC2 are not secreted by NHBE cells under these conditions. Although the amount of material was much less, mucins from the cell layer were similar to those in the gel and sol phases of the secretions with the major peak, as
shown by the carbohydrate assay, at 1.46g/ml (Figure 3e ). Absorbance at 280nm was found at To investigate the size distribution of airway MUC16 mucins, material from the void volume of the Sepharose CL-2B column was subjected to rate-zonal centrifugation. Native MUC16 mucins appeared as a broad peak suggesting that they are highly heterogeneous in size ( Figure 5a ). As expected the [ 35 S]sulphate distribution followed MUC16 (Figure 5a ). The MUC16 distribution overlapped with that of MUC5B suggesting that many of the MUC16 molecules are as large as the oligomeric MUC5B mucins (Figure 5b ). Reduction gave rise to MUC5B subunits which were smaller than the native molecules ( Figure 5d ) while MUC16 mucins migrated further into the gradient suggesting that conformational changes induced by the treatment led to an apparent increase in molecular size (Figure 5c ). When the same material was subjected to trypsin digestion followed by gel chromatography, several populations of [ 35 S]sulphate-labelled fragments, the largest of which remained in the void volume, were generated ( Figure 6 ). This shows that, as expected from the predicted sequence of MUC16, large stretches of the protein core of airway MUC16 are protected from degradation by glycan chains and that the [ 35 S]sulphate-label is incorporated into the glycosylated regions.
Cleavage of airway MUC16
To investigate if the MUC16 apoprotein from airway secretions is cleaved close to the transmembrane domain, as has been seen for MUC1, MUC3 and MUC12, the LUM16-2 antiserum as well as the LUM16-4 (recognizing the cytoplasmic tail of MUC16 -see Figure   1a ) were used to probe Western blots after SDS-PAGE of the gel phase of secretions and cell extracts from two different cultures of NHBE cells (Figure 7 ). In the secretions, the LUM16-2 antiserum strongly stained material corresponding to the large MUC16 N-terminal domain which only just entered the gel (Figure 7 , lanes 1&2). Although equal amounts of material were loaded, staining at the top of the gel was much weaker in the cell extracts ( 
DISCUSSION
To verify the specificity of the LUM16-2 antiserum and to localize MUC16, immunohistochemistry in human tracheal tissue was undertaken. The staining patterns given by the LUM16-2 antiserum and the established MUC16 antisera (M11 and OC125) were identical, indicating that LUM16-2 does recognize MUC16. Due to the putative transmembrane sequence in the apoprotein, MUC16 has been regarded as a cell-associated mucin and studies in ocular tissues show MUC16 to be present on the apical surface of the corneal and conjunctival epithelia (Argueso, Spurr-Michaud, Russo, Tisdale, & Gipson, 2003) . In our study, while there was reactivity with the antisera on the airway surface, staining was seen around the cilia rather than as a distinct layer at the apex of the epithelial cells. This made it difficult to determine whether the antibody recognized MUC16 mucins in the cell membrane or secreted molecules associated with the cilia. However, the lack of staining in the cytoplasm suggests that MUC16 mucins are not synthesized by the ciliated cells and are thus unlikely to be present in the apical membrane of these cells. In contrast, MUC16 was localized to the cytoplasm of the goblet cells and the mucous cells in the submucosal glands. This finding is supported by other studies where the mucin has been identified in airway submucosal gland cells (Nouwen, Dauwe, & De Broe, 1990) , lacrimal glands (Jäger et al., 2007) and conjunctival goblet cells (Argueso, Spurr-Michaud, Russo, Tisdale, & Gipson, 2003) . In conjunctiva, MUC16 was seen in mucin packages in the goblet cells suggesting that the molecule may be co-localized in the secretory granulae with large oligomeric mucins. Whether or not these molecules are anchored in the granule membrane or represent a "secreted" form of MUC16 is not currently known. Secreted variants have been reported for other cell-associated mucins including MUC1 (Smorodinsky et al., 1996) and MUC4 (Moniaux et al., 2000) and the existence of alternatively spliced MUC16 mRNAs lacking the transmembrane domain was reported by . Although from our data it cannot be ruled out that some MUC16 is tethered in the apical membrane of ciliated cells, it appears more likely that MUC16 on the airway surface is secreted from goblet and submucosal gland cells and subsequently entrapped within the ciliary layer. This idea is compatible with a recent suggestion that MUC16 is a component of the periciliary fluid (Sheehan, Kesimer, & Pickles, 2006) .
Western blotting confirmed the presence of MUC16 as a component of respiratory mucus from healthy individuals and in secretions from cultured airway epithelial cells. NHBE cell cultures, where the predominant gel-forming mucin is MUC5B (Thornton et al., 2000) , were thus used for studies of the structure and properties human airway MUC16. As expected from the predicted sequence, which lacks the D-domains required for oligomerization (O'Brien et al., 2001; Yin, Dnistrian & Lloyd, 2002) , MUC16 from the cells was monomeric. Secreted MUC16 mucins were very large with the bulk of the population appearing at a position between that of "native" MUC5B and MUC5B subunits upon rate-zonal centrifugation.
Assuming a similar overall conformation for the molecules, this result correlates well with the sizes predicted from the apoprotein lengths for: MUC5B subunits [5662 amino acids (Desseyn, Buisine, Porchet, Aubert, & Laine, 1998) ], MUC16 (11722 amino acids or 22152 including the N-terminal extension) and "native" MUC5B mucins comprised of two or more subunits (Thornton et al., 1999) . The apparent increase in size seen after reduction of MUC16 may be explained, for instance, by the opening of cysteine loops in the MUC16 repeat domain (O'Brien et al., 2001; Yin, Dnistrian & Lloyd, 2002) . No peptides from the extended Nterminal domain of MUC16 could be identified with mass spectroscopy, and it can thus not be determined whether the domain is present in MUC16 from the airways.
To determine if MUC16 mucins are radiolabelled and thus may correspond to mucin-like molecules identified in previous studies (Somerville et al., 1992; Svitacheva, Hovenberg, & Davies 1998; Svitacheva, & Davies, 2001) from an ovarian cancer cell-line ). In the NHBE cells, the time taken for . These data thus show that the highmolecular-mass, high-buoyant density mucin-like molecules secreted from human and bovine airway cells and tissues (Somerville et al., 1992; Svitacheva, Hovenberg, & Davies 1998; Svitacheva, & Davies, 2001 ) do correspond to MUC16, although other lower-molecular-mass molecules are also radiolabelled.
While both were present in secretions and the cell layer, the C-terminal MUC16 fragment of MUC16 was not covalently linked to the large N-terminal domain demonstrating that the apoprotein has undergone proteolysis between these regions. MUC16 has a SEA module in the C-terminal domain (O'Brien et al., 2001 ) and in MUC1, MUC3, MUC13, this module contains a conserved sequence (GSVVV) where each of these mucins may be cleaved (Palmai-Pallag et al., 2005) -with MUC1 undergoing an autocatalytic cleavage (Levitin et al., 2005) . In secreted MUC16 the most C-terminal peptide identified with mass spectroscopy was a unique peptide found at the N-terminal end of this SEA domain. The C-terminal fragment has a size (20KDa) which, allowing for potential glycosylation, would be consistent with the intracellular, putative transmembrane and extracellular domains up to a position around the centre of the C-terminal domain. These data thus point to a cleavage in the Cterminal domain of MUC16, possibly in SEA module. In MUC1, the two subunits reassociate after cleavage via non-covalent interactions between sequences in the SEA domain and the molecule exists as a heterodimer (Wreschner et al., 2002) . Due to the use of chaotrophic solvents during the isolation procedure, it was not possible to determine whether the C-and N-terminal domains of MUC16 re-associate in this way. The cellular location of MUC16, as well as the presence of the C-terminal fragment in secretions, suggest that the mechanism of MUC16 release may be different from that of other membrane-bound mucins e.g. MUC1, where the N-terminal domain is shed from the cell surface leaving the C-terminal in the membrane (Thathiah, Blobel, & Carson, 2003) . Cryofixation studies have indicated that secretion from goblet cells may, in part, occur via an apocrine mechanism involving discharge of whole secretory granules (Puchelle, Beorcia, Ménager, Zahm, & Ploton, 1991) .
Thus, if MUC16 was anchored as a cleaved heterodimer in the membrane of the secretory granules rather than in the cell membrane, the release of whole granulae into secretions could explain our observations. However, further studies are required to determine whether or not this is the case.
In conclusion, our metabolic studies show that MUC16 is radiolabelled with [3990] [3991] [3992] [3993] [3994] [3995] [3996] [3997] [4617] [4618] [4619] [4620] [4621] [4622] [4623] [4624] [5085] [5086] [5087] [5088] [5089] [5090] [5091] [5092] [5241] [5242] [5243] [5244] [5245] [5246] [5247] [5248] [5397] [5398] [5399] [5400] [5401] [5402] [5403] [5404] [5553] [5554] [5555] [5556] [5557] [5558] [5559] [5560] [5709] [5710] [5711] [5712] [5713] [5714] [5715] [5716] [5865] [5866] [5867] [5868] [5869] [5870] [5871] [5872] [6177] [6178] [6179] [6180] [6181] [6182] [6183] [6184] [6332] [6333] [6334] [6335] [6336] [6337] [6338] [6339] VLQGLLR 6154-6160 *Sequence Q96RK2 from TrEMBL.
Table 1 Peptides identified by ESI-MS-MS analysis
Gel phase from apical secretions from NHBE cells was subjected to density-gradient centrifugation, reduced and alkylated and chromatographed on a Sepharose CL-2B column.
The void volume fractions (pooled as shown in Figure 3c -pool A) were digested with trypsin and subjected to ESI-MS-MS analysis. The parent and fragment ion masses were within 50 mDa of the theoretical values. The locations of the most N-terminal and C-terminal peptides generated are shown in Figure 1a . 
